AtriCure Inc. (ATRC) is First Light Asset Management LLC’s 6th Largest Position

First Light Asset Management LLC raised its holdings in AtriCure Inc. (NASDAQ:ATRC) by 8.6% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,167,672 shares of the medical device company’s stock after buying an additional 92,225 shares during the period. AtriCure comprises approximately 5.3% of First Light Asset Management LLC’s investment portfolio, making the stock its 6th biggest holding. First Light Asset Management LLC’s holdings in AtriCure were worth $23,961,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Teacher Retirement System of Texas acquired a new position in shares of AtriCure in the fourth quarter valued at approximately $203,000. Trexquant Investment LP acquired a new position in shares of AtriCure in the first quarter valued at approximately $224,000. HBK Investments L P acquired a new position in shares of AtriCure in the fourth quarter valued at approximately $255,000. Capital Fund Management S.A. grew its position in shares of AtriCure by 57.3% in the fourth quarter. Capital Fund Management S.A. now owns 15,100 shares of the medical device company’s stock valued at $275,000 after purchasing an additional 5,500 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of AtriCure by 105.1% in the first quarter. JPMorgan Chase & Co. now owns 14,208 shares of the medical device company’s stock valued at $292,000 after purchasing an additional 7,281 shares during the last quarter. 87.52% of the stock is currently owned by institutional investors.

Several research firms have recently commented on ATRC. BidaskClub raised AtriCure from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 19th. ValuEngine raised AtriCure from a “hold” rating to a “buy” rating in a research report on Saturday, May 12th. Zacks Investment Research downgraded AtriCure from a “buy” rating to a “hold” rating in a research report on Wednesday, May 2nd. Stifel Nicolaus upped their target price on AtriCure from $22.00 to $23.00 and gave the company a “buy” rating in a research report on Friday, April 27th. Finally, Needham & Company LLC upped their target price on AtriCure from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, April 27th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $25.00.

In related news, Director Elizabeth D. Krell sold 10,000 shares of the stock in a transaction that occurred on Tuesday, May 8th. The stock was sold at an average price of $22.82, for a total transaction of $228,200.00. Following the sale, the director now owns 29,967 shares of the company’s stock, valued at $683,846.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 8.70% of the company’s stock.

AtriCure stock opened at $24.88 on Thursday. The company has a market capitalization of $850.07 million, a PE ratio of -29.98 and a beta of 0.24. AtriCure Inc. has a 12 month low of $14.88 and a 12 month high of $25.18. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.31 and a current ratio of 3.15.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Thursday, April 26th. The medical device company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.27) by ($0.04). The company had revenue of $46.99 million for the quarter, compared to analyst estimates of $45.43 million. AtriCure had a negative return on equity of 16.92% and a negative net margin of 14.88%. The company’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.32) EPS. analysts anticipate that AtriCure Inc. will post -0.86 EPS for the current year.

About AtriCure

AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure Inc. (NASDAQ:ATRC).

Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit